RecruitingPhase 2Phase 3NCT06752616
Acute Agitation in Emergency Psychiatry
Advancing the Quality of Treatment and Care for Acute Agitation in Emergency Psychiatry
Sponsor
Lone Baandrup
Enrollment
132 participants
Start Date
Dec 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.
Eligibility
Min Age: 18 YearsMax Age: 64 Years
Inclusion Criteria5
- -64 years
- Agitation with the need for tranquillization in inpatient psychiatric settings including psychiatric emergency rooms
- Total score of ≥14 on the PANSS Excited Component (PEC)
- A score ≥4 on at least 1 of the 5 items of the PEC
- Informed consent obtained prior to the occurrence of the emergency
Exclusion Criteria11
- Involuntary psychiatric admission according to the Danish Mental Health Act
- Female patients who are breastfeeding
- Female patients aged <50 years and unable to perform a negative urine screen for pregnancy and not using safe contraceptives
- Body weight <50 kg
- Extreme obesity defined as estimated BMI≥ 40 kg/m2
- Clinical situations where acute administration of an antipsychotic is preferred to treat acute agitation (in the opinion of the investigator)
- The patient deemed unwilling or unable to cooperate with study procedures (in the opinion of the investigator)
- Insufficient language skills that interfere with reading, writing, and providing written informed consent in Danish or other available languages (in the opinion of the investigator)
- Clinical suspicion of contraindications for one of the treatment arms
- Use of benzodiazepines, other sedatives, or antipsychotic drugs in addition to usual treatment (i.e., additional PN sedative prescriptions) in the 4 hours before study treatment
- Known allergy to any of the study medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSublingual Dexmedetomidine
Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs
DRUGBuccal midazolam
Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs
DRUGOral lorazepam
Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06752616
Related Trials
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
NCT060522543 locations
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT0680898452 locations
Nabilone for Agitation Blinded Intervention Trial
NCT045160576 locations
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
NCT0539763944 locations